Officinae Bio

Executive Summary

Officinae Bio is an Italian biotechnology company founded in 2020 that leverages its proprietary AI platform, Mercurius, to optimize mRNA sequence design for improved translation efficiency, tissue specificity, and stability. The company operates as a service provider, offering phase-appropriate design and optimization bundles for therapeutic developers targeting protein replacement, cancer immunotherapy, and other applications. By integrating machine learning into mRNA engineering, Officinae Bio aims to significantly accelerate discovery-to-preclinical timelines, reducing costs and increasing the probability of success for its partners. The platform's ability to enhance mRNA properties positions it as a key enabler in the rapidly growing mRNA therapeutics field, which has seen expanded interest beyond vaccines into areas such as rare diseases and oncology. As a pre-clinical stage company, Officinae Bio is focused on validating its platform through collaborative partnerships and securing funding to scale operations. The company has not yet disclosed specific revenue or funding rounds, but its strategic location in Milan provides access to Europe's biotech ecosystem. Near-term catalysts include potential initial partnerships with pharmaceutical or biotech firms seeking mRNA optimization, the completion of a Series A financing round to support platform development and commercial expansion, and the publication of preclinical data demonstrating the platform's advantages over conventional mRNA engineering approaches. Given the competitive landscape in AI-driven drug discovery, successful execution on these catalysts will be critical for Officinae Bio's growth and market positioning.

Upcoming Catalysts (preview)

• Q3 2026First commercial partnership with pharma/biotech for mRNA optimization60% success
• Q2 2026Series A financing round70% success
• Q1 2026Publication of preclinical validation data for Mercurius platform80% success